HOME >> MEDICINE >> NEWS
M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD

ORLANDO -- Researchers at The University of Texas M. D. Anderson Cancer Center reported today that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.

Francis J. Giles, M.D., professor in the Department of Leukemia at M. D. Anderson Cancer Center, presented the Phase I / II trial data today at the annual meeting of the American Society of Hematology.

According to Giles, the study of 44 patients, conducted at M. D. Anderson Cancer Center and Duke University Medical Center, showed the first clinical activity of a kinase inhibitor against the T315I BCR-ABL mutation found in chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL). In addition, the trial showed the first activity against the JAK-2 mutation found in myeloproliferative disorders (MPD), a group of blood diseases that can evolve into leukemia. MK-0457 has also been found in previous studies to inhibit Aurora kinases A, B, C and FLT3 in leukemias.

Giles reported that patients on the study experienced minimal side effects, such that no maximum tolerated dose was defined. Mild side effects included lowering of white blood cells, hair loss, nausea and inflammation of the mouth.

"MK-0457 is a drug that produces clinical and biologic activity where we have not seen it before - in T315I-positive CML and ALL and JAK-2-positive MPD. This is a very active biologic agent for patients with advanced leukemia, and has very few side effects, all of which are quite manageable," Giles said. "With the data from this trial, we have a strong rationale to take this agent forward to more definitive and larger studies."

Though CML, ALL and MPD are relatively rare cancers, they are very aggressive and often fatal after failing standard therapy, said Giles. For the subset of leukemia patients who have the T315I
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
11-Dec-2006


Page: 1 2 3

Related medicine news :

1. M.D. Anderson collaborates with Federal Ministry of Health in Nigeria
2. M. D. Anderson, BCM, launch research effort targeting asthma and allergic diseases
3. M. D. Anderson teaches the art of aromatherapy to soothe and heal
4. M. D. Anderson: Setting the benchmark in brain tumor treatment
5. International award honors M. D. Anderson President for pioneering research
6. Rice, M. D. Anderson win funds for bench to bed training
7. Newest M.D. Anderson SPORE to fund breast cancer research
8. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
9. Red and Charline McCombs contribute $30 million to M. D. Anderson research effort
10. M. D. Anderson announces collaboration with Indias largest yoga research institution
11. New study reports hotel guests at risk from carbon monoxide poisoning

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/16/2018)... ... November 16, 2018 , ... ... framework agreements with China Resources Microelectronics Limited (CR Micro) and China Resources ... the possibility of establishing two joint research centres for novel micro-electronic devices ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) have elected Edward D. Buckingham, ... in the specialty field of facial plastics and reconstruction, while AAFPRS is an ...
(Date:11/15/2018)... ... 15, 2018 , ... Over the last decade, SABRE , the global ... for National Breast Cancer Foundation (NBCF) . A mission-driven organization and proud partner ... proceeds have helped launch the National Mammography Program which has provided almost ...
(Date:11/15/2018)... ... November 15, 2018 , ... ApriaDirect, ... now accepts Flexible Spending Account (FSA) and Health Savings Account (HSA) debit cards ... burden of healthcare spending for customers and improve the overall shopping experience. ...
(Date:11/15/2018)... ... November 15, 2018 , ... The National Cancer Institute estimates that 1.7 million ... primary risk factor for cancer and we typically associate the disease with old age, ... And with aggressive treatment and advanced therapies, increasing numbers of these patients survive their ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 16, 2018 , ... Drake’s Organic Spirits ... Certification by the globally-recognized and respected Vegan Awareness Foundation. Drake’s is the ... Vegan, Non-GMO Project Verified, Gluten-Free and Kosher. , Many consumers assume ...
(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... Ric Henry, ... Health Care Center in Truth or Consequences, New Mexico on Friday, November 2, 2018. ... President of the Center’s Board of Directors. , Sierra Health Care Center has ...
(Date:11/15/2018)... ... November 15, 2018 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that Pete Young, Director of ... Partnerships in Clinical Trials (PCT) conference at the CCIB Convention Centre Barcelona, Barcelona, ...
Breaking Medicine Technology:
Cached News: